Omtriptolide (sodium)

Omtriptolide sodium (PG490-88Na) is a derivative of Triptolide (HY-32735) . Omtriptolide sodium exhibits significant immunosuppressive, anti-fibrotic and anti-inflammatory properties. The mechanism of action of Omtriptolide sodium is diverse, including inhibiting T cell activation and proliferation, inducing T cell apoptosis (apoptosis), blocking fibroblast maturation/proliferation, inhibiting TGF-β mRNA expression, and suppressing pro-inflammatory cytokines (such as IL-2, IFN-γ, TNF-α) by blocking transcription factors such as NF-κB. Omtriptolide sodium can be used for research on obstructive airway diseases, pulmonary fibrosis and graft-versus-host disease[1][2][3][4].

Product Specifications

CAS Number

[195883-09-1]

Product Name Alternative

PG 490-88Na

UNSPSC

12352005

Target

Apoptosis; IFNAR; Interleukin Related; NF-κB; TGF-β Receptor; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation; NF-κB; TGF-beta/Smad

Field of Research

Inflammation/Immunology

Smiles

O=C1OCC2=C1CC[C@@]3(C)[C@@]2([H])C[C@H]4[C@@]5(O4)[C@H](OC(CCC(O[Na])=O)=O)[C@]6(C(C)C)[C@@H](O6)[C@H]7[C@]53O7

Molecular Formula

C24H27NaO9

Molecular Weight

482.46

References & Citations

[1]Chen BJ, et al. Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion. Transplantation. 2000 Nov 27;70 (10) :1442-7.|[2]Krishna G, et al. PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis. Am J Pathol. 2001 Mar;158 (3) :997-1004.|[3]Leonard CT, et al. PG490-88, a derivative of triptolide, attenuates obliterative airway disease in a mouse heterotopic tracheal allograft model. J Heart Lung Transplant. 2002 Dec;21 (12) :1314-8.|[4]Kim HJ, et al. The water-soluble triptolide derivative PG490-88 protects against cisplatin-induced acute kidney injury. J Pharmacol Exp Ther. 2014 Jun;349 (3) :518-25.